ReviewHereditas2025
Research landscape of photodynamic therapy for hepatocellular carcinoma: Hotspots and Prospects from 2012 to 2025.
Review in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Current Status and Emerging Trends in Global Research on Liposome Therapy for Hepatocellular Carcinoma: A Bibliometric Analysis.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the current status and future development of photodynamic therapy (PDT) for hepatocellular carcinoma (HCC). However, this field lacks a comprehensive bibliometric analysis. This study aims to investigate the research content and hotspots in PDT for liver cancer from 2012 to 2025, and to predict future research directions, providing references for subsequent studies.
methodsWe chose the Web of Science Core Collection (WoSCC) database and retrieved articles published in the field between 2012 and 2025. Bibliometric and visualization analyses were performed using R (version 4.4.1), VOSviewer (version 1.6.19), and CiteSpace (version 6.4. R1).
resultsA total of 547 papers were included. We found that the number of publications in this field has steadily increased from 2012 to 2025. China leads with the highest number of publications, followed by the USA, Korea, Germany, and Japan. China has the lowest international co-authorship rate, while Germany and Japan show higher international collaboration rates. The International Journal of Nanomedicine is the most popular journal for publication, whereas Biomaterials ranks first in terms of citations. Our analysis of keywords and the most cited references revealed that current research focuses on the mechanism of PDT-induced apoptosis in HCC, the development of photosensitizers (PSs), nanotechnology-enhanced PDT, and synergistic treatment of HCC with PDT and other therapies. Nanotechnology and multimodal synergistic therapeutic strategies are driving the treatment of HCC.
conclusionPDT, as a therapy for HCC, is expected to become a research hotspot. This paper analyzes PDT's current research for HCC, offering references for future research in related fields.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.